Pathological Conditions, Signs and Symptoms

144 trials 75 recruiting

Filter these 144 trials by phase, country and sponsor.

Open in Search →

Investigating How Anti-Infection Drugs Are Processed in the Bodies of Healthy People and Severely Burned Patients in the Intensive Care Unit Recruiting

2024-517260-39-00 Combustion 3 2017-09-15
A Study to Establish the Bioequivalence of Free Acid Tafamidis 61 mg Capsule and Tablet, and Evaluate the Safety and Tolerability of the 61 … Ended

2026-525342-29-00 Transthyretin amyloidosis 2 2026-03-16
A Study Evaluating Monthly (Every 4 Weeks) Dosing of Atacicept in Patients with IgAN Ended

2025-521519-37-00 IgA Nephropathy (IgAN); Berger Disease; Renal and Urina 4 2025-10-10
A phase 1/2a multicenter trial to evaluate the safety and immunogenicity of the CD40.Pan.CoV vaccine, adjuvanted or not, as a booster in adu… Ended

2024-516767-92-01 Health Participants 1 2025-06-17
VALSARTAN TREATMENT COMPARED IN RENAL TRANSPLANT RECIPIENTS WITH SIGNS OF POST TRANSPLANT GLOMERULOPATHY Ended

2024-518723-30-01 Renal transplant patients 6 2024-10-16
SAFETY AND FEASIBILITY OF IRRADIATION AND NIVOLUMAB IN ESOPHAGEAL CANCER (INEC-STUDY) – A PHASE I/II TRIAL Ended

2023-510124-77-01 Eosophageal cancer 9 2024-09-28
BELASBRIDGE : Belatacept as a replacement for CNIs 3 to 12 months post-transplantation in patients with early graft dysfunction Ended

2022-500299-71-00 Kidney transplant 4 2024-05-03
An Open-Label Multicenter Phase 1b Study of Tolinapant (ASTX660) in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative… Ended

2024-511963-28-00 Neoadjuvant therapy in locally-advanced rectal cancer 3 2023-12-19
Open-Label and Long-term Extension Study with Dersimelagon (MT-7117) in Subjects with EPP or XLP Ended

2024-514466-38-00 Erythropoietic Protoporphyria (EPP) or X-Linked Protopo 5 2022-04-19
ANRS HB07 IP-Cure-B proof of concept (PoC) clinical trial. Educating the liver immune environment through TLR8 stimulation followed by NUC d… Ended

2024-515739-32-00 HBV 4 2022-01-10
Atacicept in Subjects with IgA Nephropathy (ORIGIN and ORIGIN 3) Ended

2023-503772-24-00 IgA Nephropathy 10 2021-09-15
GYNET : A randomized, multicenter, open label, Phase I/II study to evaluate the safety (Phase I - safety run in), clinical and biological ac… Ended

2024-510714-32-00 Patiens with locally advanced/metastatic endometrial ca 4 2020-12-10
Effectiveness and Safety of Sparsentan as treatment for Immunoglobulin A Nephropathy (IgAN) Ended

2023-505495-30-00 Immunoglobulin A Nephropathy (IgAN) 5 2019-02-01
MIVAR - Milrinone Infusion for VAsospam treatment in subarachnoid hemoRrhage Ended

2024-515994-83-00 aneurysmal subarachnoid hemorrhage with a vasospasm 5 2026-01-13
Bioequivalence of two transdermal therapeutic systems delivering 100 mcg/h fentanyl Ended

2023-504698-19-00 Bioequivalence trial in healthy volunteers 2 2025-05-30
Accelerator-based BNCT for head and neck carcinoma Ended

2024-515036-71-00 Head and neck carcinoma 3 2025-04-15
Midazolam and morphine to alleviate symptoms at the end of life in patients on acute geriatric wards Ended

2024-517763-22-00 Symptom treatment in the last days of life of geriatric 6 2025-02-03
BATOLISA Ended

2024-513529-21-00 Lipedema 6 2025-01-24
A relative bioavailability study between a fixed dose combination product of Ibuprofen and Paracetamol vs. free combination of Ibuprofen a… Ended

2024-516423-14-00 cold and flu 2 2024-12-19
A study to establish the bioequivalence of free acid tafamidis 61 mg capsule and tablet, and evaluate the safety and tolerability of the 61 … Ended

2024-514166-40-00 Transthyretin amyloidosis 2 2024-12-16
A Phase 1, randomized, double blind, single center, placebo controlled, single escalating weight-adjusted dose, safety study of HI-6 dimethy… Ended

2023-509020-17-00 Treatment of patients poisoned with organophosphorus co 1 2024-11-25
A randomized, single-center, double-blind, placebo-controlled, first-in-human trial with single and multiple ascending doses to determine sa… Ended

2024-512510-17-00 Treatment of pain 1 2024-08-05
Personalized Treatment Optimization for Kidney Health in Type 2 Diabetes: A Remote Trial with Empagliflozin and Finerenone Ended

2023-508585-15-00 Albuminuria 6 2024-07-29
A Single-blind, Phase 2, Multi-center, Randomized Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of the Relaxin Agonist… Ended

2023-503504-88-00 Hepatorenal Syndrome – Acute Kidney Injury 4 2024-05-13